Grifols (NASDAQ:GRFS) Rating Lowered to “Hold” at Wall Street Zen

Posted by Stanley Muller on Oct 12th, 2026

Grifols (NASDAQ:GRFS – Get Free Report) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.

GRFS has been the topic of several other reports. Zacks Research raised shares of Grifols from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. Weiss Ratings raised Grifols from a “sell (d)” rating to a “sell (d+)” rating in a research report on Monday, August 17th. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $10.00.

View Our Latest Research Report on Grifols

Grifols Stock Performance

NASDAQ GRFS opened at $7.46 on Friday. Grifols has a 52 week low of $6.96 and a 52 week high of $9.90. The company has a 50 day moving average price of $7.67 and a 200 day moving average price of $7.74. The company has a quick ratio of 0.81, a current ratio of 2.37 and a debt-to-equity ratio of 1.10. The firm has a market cap of $5.08 billion, a PE ratio of 39.26, a price-to-earnings-growth ratio of 0.27 and a beta of 0.70.

Hedge Funds Weigh In On Grifols

Hedge funds and other institutional investors have recently modified their holdings of the stock. Armistice Capital LLC lifted its stake in shares of Grifols by 23.8% during the fourth quarter. Armistice Capital LLC now owns 2,768,000 shares of the biotechnology company’s stock worth $25,881,000 after buying an additional 532,000 shares during the period. Flat Footed LLC grew its holdings in shares of Grifols by 26.5% during the first quarter. Flat Footed LLC now owns 1,372,394 shares of the biotechnology company’s stock valued at $11,007,000 after buying an additional 287,867 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S grew its holdings in shares of Grifols by 466.3% during the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 316,111 shares of the biotechnology company’s stock valued at $2,535,000 after buying an additional 260,295 shares during the last quarter. Tidal Investments LLC grew its holdings in shares of Grifols by 9.8% during the second quarter. Tidal Investments LLC now owns 1,233,082 shares of the biotechnology company’s stock valued at $8,730,000 after buying an additional 109,612 shares during the last quarter. Finally, Royal Bank of Canada increased its position in shares of Grifols by 15.4% in the 1st quarter. Royal Bank of Canada now owns 785,703 shares of the biotechnology company’s stock valued at $6,301,000 after acquiring an additional 104,850 shares during the period.

Grifols Company Profile

(Get Free Report)

Grifols SA is a global healthcare company based in Barcelona, Spain, and is listed on Nasdaq under the symbol GRFS. Founded in 1909, the company is primarily focused on developing, manufacturing and supplying plasma-derived medicines and other healthcare products.

Its principal therapies include immunoglobulins, albumin, alpha-1 antitrypsin and coagulation factors, which are used to treat immune deficiencies, respiratory disorders, bleeding conditions and other serious diseases. Grifols operates a network of plasma donation centers, mainly in the United States and Europe, to collect the source plasma used in its medicines.

Grifols also provides diagnostic solutions, including instruments and reagents used in blood typing, transfusion medicine and laboratory testing.